Holen Sie sich die Stockscreener-App
7.60
0.39%
-0.03
Handel nachbörslich:
7.55
-0.05
-0.66%
Schlusskurs vom Vortag:
$7.63
Offen:
$7.72
24-Stunden-Volumen:
413.64K
Relative Volume:
1.12
Marktkapitalisierung:
$179.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.07M
KGV:
-36.59
EPS:
-0.2077
Netto-Cashflow:
$-44.93M
1W Leistung:
+1.88%
1M Leistung:
-0.52%
6M Leistung:
-19.75%
1J Leistung:
-24.47%
1-Tages-Spanne:
$7.41
$7.75
1-Wochen-Bereich:
$7.2202
$7.75
52-Wochen-Spanne:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Firmenname
Cybin Inc
Sektor
Branche
Telefon
908 764 8385
Adresse
100 King Street West, Suite 5600, Toronto
Vergleichen Sie CYBN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.60 | 179.99M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Yahoo Finance
Cybin Inc. Amends Convertible Note Agreement with High Trail - TipRanks
Cybin gains Irish Medicines Board approval for major depressive disorder trial - Yahoo Finance
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace
Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe. - AInvest
Psychedelic: Cybin receives European approval for EMBRACE study - TipRanks
Cybin receives European approval for EMBRACE trial - TipRanks
Cybin Gets European Approval For EMBRACE Study Of CYB003 For Major Depressive Disorder - Nasdaq
Cybin Secures European Approval for EMBRACE Study in Major Depressive Disorder - TipRanks
Cybin receives European approval for phase 3 depression drug trial By Investing.com - Investing.com Nigeria
Cybin receives European approval for phase 3 depression drug trial - Investing.com
Cybin CEO to Speak at Canaccord Genuity Growth Conference - TipRanks
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
Is Cybin Inc. the Top Chart Pick This WeekPortfolio Diversification Stock Ideas From Experts - beatles.ru
What are the latest earnings results for Cybin Inc.Achieve rapid wealth accumulation through smart investing - Jammu Links News
Cybin Inc. Stock Analysis and ForecastFree Market Dynamics Reports - Jammu Links News
How volatile is Cybin Inc. stock compared to the marketCapitalize on emerging investment opportunities - Jammu Links News
What institutional investors are buying Cybin Inc. stockCapitalize on market trends before they peak - Jammu Links News
What are analysts’ price targets for Cybin Inc. in the next 12 monthsUnlock powerful market analysis and alerts - Jammu Links News
Is Cybin Inc. stock overvalued or undervaluedUnstoppable trading performance - Jammu Links News
How many analysts rate Cybin Inc. as a “Buy”Achieve consistent profits with proven methods - Jammu Links News
Is Cybin Inc. a good long term investmentSuperior profit margins - Jammu Links News
When is Cybin Inc. stock expected to show significant growthAchieve breakthrough financial results - Jammu Links News
Why is Cybin Inc. stock attracting strong analyst attentionInvest smarter with data-backed trading alerts - Jammu Links News
What are Cybin Inc. company’s key revenue driversGet expert insights on market-moving stocks - Jammu Links News
Cybin Announces $1 Billion Mixed Securities Shelf Filing to Enhance Financial Flexibility - AInvest
Cybin Inc. Schedules Virtual Annual General Meeting for August 2025 - MSN
Cybin Inc. May Be Forming Higher Low — Chartwatchers AlertFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Should I hold or sell Cybin Inc. stock in 2025Real Time Insights For 2025 - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockFree Risk Assessment Services - Jammu Links News
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - Jammu Links News
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - metal.it
Finanzdaten der Cybin Inc-Aktie (CYBN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
Kapitalisierung:
|
Volumen (24h):